Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Genmab A/S before investing.

In this article, we go over a few key elements for understanding Genmab A/S’s stock price such as:

• Genmab A/S’s current stock price and volume
• Why Genmab A/S’s stock price changed recently
• Upgrades and downgrades for GMAB from analysts
• GMAB’s stock price momentum as measured by its relative strength

About Genmab A/S (GMAB)

Before we jump into Genmab A/S’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter’s syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.

Want to learn more about Genmab A/S’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Genmab A/S.

Genmab A/S’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Genmab A/S’s stock price was $28.870.

Genmab A/S is up 0.8% from its previous closing price of $28.640.

During the last market session, Genmab A/S’s stock traded between $28.230 and $28.930. Currently, there are approximately 63.10 million shares outstanding for Genmab A/S.

Genmab A/S’s price-earnings (P/E) ratio is currently at 2.2, which is low compared to the Biotechnology industry median of 18.6. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Genmab A/S Stock Price History

Genmab A/S’s (GMAB) price is currently up 5.1% so far this month.

During the month of July, Genmab A/S’s stock price has reached a high of $29.800 and a low of $27.330.

Over the last year, Genmab A/S has hit prices as high as $35.430 and as low as $20.995. Year to date, Genmab A/S’s stock is down 6.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Genmab A/S Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there was 1 analyst who downgraded Genmab A/S’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Genmab A/S’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Genmab A/S’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Genmab A/S’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Genmab A/S (GMAB) by visiting AAII Stock Evaluator.

Relative Price Strength of Genmab A/S

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Genmab A/S has a weighted four-quarter relative price strength of 4.04%, which translates to a Momentum Score of 66 and is considered to be Strong.

Want to learn more about how Genmab A/S is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Genmab A/S Stock Price: Bottom Line

As of July 31, 2026, Genmab A/S’s stock price is $28.870, which is up 0.8% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Genmab A/S stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.